La cadena de opciones muestra datos clave de las opciones de acciones de Athira Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Athira Pharma..

Athira Pharma (NASDAQ:ATHA) Bolsa, Cadena de Opciones

Athira Pharma

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma Inc

Atha Energy Corp

Athabasca Minerals Inc

ATHABASCA OIL CORP by Athabasca Oil Corp.

Athabasca Oil Corp

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and recommended buying the same. &#8220;I think you've got a <a href="https://www.benzinga.com/quote/NEE/earnings">good one,&#8221; he added</a>.
On Jan. 24, NextEra Energy Inc posted in-line earnings for the fourth quarter and said it continues to expect adjusted EPS of $3.45-$3.70 for FY25.
<h3 class="wp-block-heading">Cramer&#8217;s Take On Tech Stocks</h3>
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) has missed the quarter too often, Cramer said. &#8220;If you want to be in that, you want to be in Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>).&#8221; The San Francisco-based company will release financial results for the fourth quarter after the closing bell on Wednesday, Feb. 12.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) is &#8220;up in a straight line, it's a parabolic move.&#8221; He noted that although it's a good company, but he can't recommend parabolic stocks. &#8220;Let that one come in,&#8221; he added. The San Jose, California-based company, on Feb. 4, posted better-than-expected earnings for its fourth quarter.</li>
</ul>
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been bad for him, the Mad Money host said. &#8220;That last quarter was terrible, and, frankly, they were very smug on the call talking about how good it was, and that was a very ill-advised strategy that they adopted, and I don't like it.&#8221;
Supporting his view, Raymond James analyst Andrew Cooper, on Feb. 3, downgraded Danaher from Outperform to Market Perform.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is Jeffrey Gendell's [Chief Executive Officer for IES Holdings] company, Cramer said. &#8220;He is a, just an amazing man.&#8221;
As per the recent earnings report, IES, on Tuesday, reported quarterly earnings of $2.64 per share, up from $1.86 per share from the same period last year. The company reported $749.50 million in sales during the quarter, compared to $634.40 million the same period last year.
Cramer said Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is a &#8220;really great&#8221; company, but he doesn't want to recommend the stock. &#8220;It's the best house in a bad neighborhood, and we don't want to be in bad neighborhoods,&#8221; he added.
In the recent news, Schlumberger's OneSubsea joint venture on Tuesday entered an agreement with Vår Energi to deliver a subsea production systems work scope, aimed at supporting multiple upcoming oil and gas developments on the Norwegian Continental Shelf.
Price Action:
<ul>
<li>NextEra Energy shares gained 0.1% to settle at $69.27 on Thursday.</li>
<li>Fastly shares dipped 2.4% to close at $9.99 during the session.</li>
<li>Danaher shares fell 1% to settle at $210.01.</li>
<li>IES shares climbed 8.4% to close at $242.10 on Thursday.</li>
<li>SLB shares fell 1.9% to settle at $40.05.</li>
<li>A10 Networks shares fell 1.3% to close at $20.55 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43536198/top-2-industrials-stocks-that-are-ticking-portfolio-bombs">Top 2 Industrials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

ATEN

FSLY

IESC

Jim Cramer Likes This Utilities Stock: 'I Think You've Got A Good One'

Needham analyst Mike Matson maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and lowers the price target from $112 to $108.

Price Target

Analyst Ratings

Needham Maintains Buy on Haemonetics, Lowers Price Target to $108

The Large MUAP Models (LMM) AI-powered neural gesture technology enables personalized, intuitive interactions for the AI and XR era
Yokneam Illit, Israel, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), an award-winning pioneer in artificial intelligence ("AI")-based wearable gesture control technology, is proud to announce a groundbreaking advancement in human-computer interaction: Large MUAP Models ("LMM"). Building on the success of LLMs in natural language processing, Wearable Devices is actively developing LMMs with the goal to revolutionize how we interact with digital devices, aiming to offer personalized, intuitive gesture control powered by neural data.
While still in development, this innovative technology, as previously announced, holds immense potential to redefine human-device interaction.

WLDS

Wearable Devices Announces The Large MUAP Models AI-powered Neural Gesture Technology Enables Personalized, Intuitive Interactions For The AI And XR Era

Freedom Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRHC#NASDAQ">FRHC</a>) reported quarterly earnings of $1.29 per share. This is a 20.86 percent decrease over earnings of $1.63 per share from the same period last year. The company reported $655.19 million in sales this quarter. This is a 56.51 percent increase over sales of $418.63 million the same period last year.

Earnings

FRHC

Freedom Holding Q3 EPS $1.29 Down From $1.63 YoY, Sales $655.19M Up From $418.63M YoY

U.S. stock futures were mixed this morning, with the Dow Jones futures gaining around 0.1% on Friday.
Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results and issued first-quarter guidance <a href="https://www.benzinga.com/quote/SKX/earnings">below estimates</a>.
Skechers reported quarterly earnings of 65 cents per share which missed the analyst consensus estimate of 74 cents per share. The company reported quarterly sales of $2.21 billion which missed the analyst consensus estimate of $2.22 billion.
Skechers U.S.A. shares dipped 12.1% to $66.49 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) shares fell 28.4% to $68.89 in pre-market trading after the company issued third-quarter total revenue guidance below estimates.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares tumbled 25.2% to $66.17 in pre-market trading after the company issued FY25 guidance below estimates.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) fell 22% to $0.0660 in pre-market trading.</li>
<li>LiveRamp Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) declined 15.4% to $30.01 in pre-market trading as the company posted third-quarter results.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) shares dipped 11.7% to $20.51 in pre-market trading. Concentra&#xAE; Group Holdings Parent will release the financial results for its fourth quarter on Monday, March 3, after the closing bell.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 8.1% to $13.52 in pre-market trading. CVRx recently reported mixed fourth-quarter financial results.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) fell 6.6% to $49.60 in pre-market trading as the company reported weaker-than-expected third-quarter financial results and issued weak earnings guidance for the fourth quarter.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) declined 4.6% to $117.20 in pre-market trading following fourth-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in">Jim Cramer Says Don&#8217;t Buy This Financial Stock At This Level: &#8216;Let It Come In&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

BILL

CVRX

ILMN

MCHP

RAMP

Skechers Posts Downbeat Results, Joins e.l.f. Beauty, LiveRamp And Other Big Stocks Moving Lower In Friday's Pre-Market Session

In a market obsessed with the usual suspects—Nvidia Corp, Tesla Inc and Palantir Technologies Inc — one stock has been quietly <a href="https://www.benzinga.com/quote/APP/news">stealing the show</a>: AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>).
While Wall Street fawns over AI chips and self-driving tech, APP has been quietly outperforming nearly every major stock in the Nasdaq 100—and it's not even close.
<h2 class="wp-block-heading">Let's Talk Numbers</h2>
Over the past year, APP stock has soared 698%, making it the top-performing stock in the Nasdaq 100. Even in the last six months, it's up a staggering 466%, comfortably beating Palantir's 323% and MicroStrategy Inc&#8217;s 161%. Big-name AI darlings like Nvidia and Tesla? They aren't even in the same league.
So, what's fueling this relentless rally? 
AI-powered mobile advertising. 
Headquartered in Palo Alto, AppLovin has found its sweet spot in the mobile app ecosystem, helping businesses reach and monetize audiences through its AI-driven marketing software. And with digital ad spending continuing to climb, AppLovin is cashing in big.
Read Also: <a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a>
<h2 class="wp-block-heading">Technicals Are Screaming &#8216;Bullish&#8217;</h2>
APP stock isn't just riding hype—it's riding strong technical momentum. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07061114/Screenshot-2025-02-07-at-4.40.55-PM.png" alt="" class="wp-image-771419" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07061114/Screenshot-2025-02-07-at-4.40.55-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07061114/Screenshot-2025-02-07-at-4.40.55-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020725&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
APP stock is currently trading at $380.63, well above key moving averages:
<ul>
<li>Eight-day SMA: $369.60</li>
<li>20-day SMA: $350.97</li>
<li>50-day SMA: $344.82</li>
<li>200-day SMA: $171.10 </li>
</ul>
Add in a MACD (moving average convergence/divergence) of 12.08 and an RSI (relative strength index) of 61.64, and APP stock is flashing bullish signals across the board. 
Translation? Buyers are in control, and momentum remains strong.
<h2 class="wp-block-heading">The Big Test: Q4 Earnings</h2>
The next major catalyst? Fourth quarter earnings on Feb. 12. Wall Street is eyeing $1.24 EPS on $1.26 billion in revenue according to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020725&amp;t=be2bearmibe3na1">Benzinga Pro</a> data. Given AppLovin's track record, a blowout quarter could send shares even higher.
At this pace, AppLovin is rewriting the script on Nasdaq 100 winners—and proving that sometimes, the best bets aren't the most obvious ones.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43552113/pinterests-ai-taste-graph-expands-75-as-meta-rival-hits-first-1-billion-revenue-quarter">Pinterest&#8217;s AI &#8216;Taste Graph&#8217; Expands 75% As Meta-Rival Hits First $1 Billion Revenue Quarter</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Technicals

Previews

Tech

Applovin Emerges As Nasdaq 100's Dark Horse In A Market Fixated On Nvidia, Tesla, Palantir

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $190 to $185.

NBIX

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $185

Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a leading wellness and dietary supplement company, today announced a significant order for its flagship product, Sure Shot, from a prominent Midwestern grocery chain with over 285 stores across eight states. This partnership, initially announced in late 2024, marks a major milestone in Safety Shot's retail expansion strategy. The substantial order of 150 cases, equivalent to 600 six packs.

Contracts

SHOT

Safety Shot Announces Order Of Sure Shot With Midwestern Grocery Chain Across 285 Stores In 8 States, Boosting Retail Expansion Strategy With 150 Cases Order

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1114925/000168316825000795/lantronix_s3.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1114925/000168316825000795/lantronix_s3.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1114925/000168316825000795/lantronix_s3.htm</a>

Offerings

LTRX

Lantronix Files For Offering Of Common Stock Of Up To $100M

Preliminary Full Year 2024 Financial Results1
<ul>
<li>The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024.</li>
<li>Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million for the prior year.</li>
<li>Capital expenditures was approximately $0.1 million, compared to $29.1 million for the prior year.</li>
<li>Net operating loss was approximately $126.6 million, which includes non-cash impairment charges of approximately $59.0 million, compared to net operating loss of $116.7 million for the prior year.</li>
<li>The Company announced that net revenue from the sale of its marketed products was approximately $10.1 million, compared to $7.8 million for the prior year.</li>
<li>On February 3, 2025, the Company repaid a mortgage (Loan and Guaranty Agreement) with JGB Capital and related parties that was secured by two facilities and the Company is now debt-free.</li>
</ul>
The Company expects that its cash resources at December 31, 2024, and the gross proceeds of approximately $30.4 million raised from sales under its at-the-market facility in the first quarter of 2025, will be sufficient to fund its planned operations into the first quarter of 2026.

Guidance

TNXP

Tonix Pharmaceuticals Reports FY24 Preliminary Financials: $98.8M In Cash And Cash Equivalents As Of December 31, 2024, Revenue Hits ~$10.1M Vs $7.8M YoY

Biotech

General

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Announces That Avon Freight Group Has Selected Its Non-Invasive Intelligent Fingerprinting Drug Testing Solution For Random Drug Testing Across Its Three UK Sites

Financing

REBN

Reborn Coffee Enters Securities Purchase Agreement And Common Stock Purchase Agreement For Up to $60M In Financing Commitments With Arena Investors, LP And Arena Business Solutions Global SPC II, Ltd.

TD Securities analyst Andrew Charles maintains Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) with a Hold and raises the price target from $140 to $151.

TD Securities Maintains Hold on Yum Brands, Raises Price Target to $151

CENN

Cenntro Says Delivered Over 1,000 Autonomous Driving Delivery Vehicles Incorporating iChassis 100 In 2024 To Third-Party Contractors In China In 2024

Mizuho analyst Ben Chaiken maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $263 to $272.

Mizuho Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $272

Macro Economic Events

Econ #s

Economics

USA Participation Rate For January 62.6% ; 62.5% Prior

Garry Black, Managing Partner of The Future Fund LLC, highlighted Wall Street&#8217;s continued confidence in Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) despite the company&#8217;s disappointing revenue forecast<a href="https://www.benzinga.com/25/02/43545590/amazoncom-q4-earnings-highlights-revenue-beat-eps-beat-most-successful-holiday-shopping-season-in-company-history"> for the first quarter of 2025.</a>
What Happened: In a post on X today, Black noted that out of 84 analysts, 79 rated Amazon as a &#8216;Buy&#8217;. This comes despite the e-commerce giant&#8217;s revenue guidance for the first quarter of 2025 falling short of expectations.
Despite the weak guidance, several financial analysts have recently increased their price targets for Amazon, indicating a positive outlook for its future performance. Piper Sandler raised its target to $265 from $225, DA Davidson to $280 from $285, and Canaccord Genuity to $280 from $265, among others, as per Black&#8217;s post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24AMZN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMZN</a> PT increases <a href="https://t.co/KWUsym5g6v">pic.twitter.com/KWUsym5g6v</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1887840387991064953?ref_src=twsrc%5Etfw">February 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43551924/amazons-rufus-is-changing-how-you-shop-andy-jassy-explains-how-the-ai-assistant-is-helping-customers-overcome-information-overload">Amazon&#8217;s Rufus Is Changing How You Shop — Andy Jassy Explains How The AI Assistant Is Helping Customers Overcome Information Overload</a>
Why It Matters: Amazon&#8217;s fourth-quarter earnings report, released on Feb 6 after market close, showed a 10% year-on-year increase in revenue, reaching $170 billion, and a near doubling of net income to $20 billion. However, the company&#8217;s first quarter 2025 sales forecast of $151 billion to $155.5 billion fell short of the anticipated $158.5 billion, attributed to an &#8220;unusually large, unfavorable impact&#8221; from foreign exchange rates. This news led to a 2.65% decline in <a href="https://www.benzinga.com/25/02/43555871/amazon-declines-3-in-friday-pre-market-whats-going-on">Amazon&#8217;s stock in pre-market trading today.</a>
Although the initial response to the guidance was negative, this reaction from Wall Street analysts, as highlighted by Black, underscores the investment community&#8217;s belief in Amazon&#8217;s strategic investments in AI and cloud computing as key drivers for future revenue growth and margin improvements. The price target increases also underscores Wall Street&#8217;s focus on Amazon&#8217;s long-term growth potential rather than short-term revenue misses.
Amazon.com Inc has a consensus price target of $256.98 based on the ratings of 41 analysts, tracked by<a href="http://pro.benzinga.com"> Benzinga Pro.</a>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AMZN/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07082929/Screenshot-2025-02-07-at-6.59.14%E2%80%AFPM-1024x394.png" alt="" class="wp-image-771711" /></a></figure>
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43551087/gary-black-says-teslas-insufficiently-robust-autonomous-network-to-compete-with-ubers-170-million-users-draws-parallels-to-amazons-e-commerce-domination">Gary Black Says Tesla&#8217;s Autonomous Network Won&#8217;t Make Uber Irrelevant, Cites Amazon As An Example Of Why Ride Hailing Middlemen Will Survive</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AMZN

Gary Black Sees 'Flurry' Of Price Target Increases For Amazon Stock Despite Weak Guidance: 'This Is How Wall Street Works'

Rosenblatt analyst Catharine Trebnick maintains Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Buy and maintains $10.5 price target.

Rosenblatt Maintains Buy on Sprinklr, Maintains $10.5 Price Target

Jan Nonfarm Payrolls +143K vs +169K Est.; Prior +307K

Former vice-president-turned-climate-change activist Al Gore has put his Arlington, Virginia, home up for rent. The asking price is $9,000 per month. Though that number would be considered high anywhere else, it&#8217;s hardly out of the ordinary in the <a href="https://www.benzinga.com/markets/25/01/43349310/mark-zuckerberg-reportedly-buying-property-in-washington-dc-as-meta-ceo-looks-to-work-closely-with-t">sought-after D.C. suburb</a> filled with wealthy politicians, lobbyists, and businessmen. What is out of the ordinary is the former politician&#8217;s net worth—$300 million.
Firstly, about the rental. The 6,207 square foot, five bedroom, four bathroom brick, Tudor style home was built in 1937 by the grandfather of Gore's ex-wife, Mary &#8220;Tipper&#8221; Gore, and has remained in the family since. It was used as the launch pad for Gore&#8217;s political career and was the base his family returned to after his loss to George W. Bush in the 2000 election. Though traditional from the exterior, the interior is spacious and stylish with contemporary finishes. However, Gore no longer lives there. He currently resides in a 400-acre farm in Carthage, Tennessee.
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-y2">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Climate Change And Changing Financial Fortunes</h2>
Gore&#8217;s climate change activism and investing have proved highly lucrative for Bill Clinton&#8216;s former second in command. According to the Daily Mail, Gore set up Generation Investment Management with former Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) managing director and close friend David W. Blood. The company&#8217;s goal was to back eco-friendly companies. Between 2008 and 2011, the firm generated about $218 million in profits to be split among its 26 partners, of which Gore is one.
In 2023, the firm was estimated to be worth $36 billion, thanks to its ownership of large numbers of shares in highly successful companies such as <a href="https://www.benzinga.com/media/25/01/43352019/amazon-cuts-more-jobs-in-cost-saving-push-report">Amazon</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSF#NASDAQ">MSF</a>), Google parent Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>, GOOGL)), Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), and Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), as well as lesser-known e-bike and e-scooter companies.&nbsp;
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-y2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a>
In addition to his role at the company, which pays him a lucrative $2 million a month, Gore is popular on the speaking circuit. He speaks on the perils of climate change and earns $200,000 per speaking engagement.&nbsp;
<h2 class="wp-block-heading">Real Estate</h2>
Gore owns multiple homes across the U.S. These include a condo in the Regis Building in San Francisco, close to the hub of many of his investments, worth around $3 million, a large colonial home in Nashville, valued at $7.5 million, a Mediterranean-style residence in Montecito, California, valued at $13 million, and his Arlington home, worth at least $3 million.&nbsp;
<h2 class="wp-block-heading">Tech Triumphs</h2>
Aside from his Green Investment Management, Gore owns tech behemoths Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Google and, until recently, drew a salary from <a href="https://www.benzinga.com/markets/equities/25/01/43374851/gene-munster-says-apples-mess-wasnt-as-big-as-it-looked-as-iphone-maker-delivers-better-than-expected-results">Apple</a> as a compensation committee member. According to<a href="https://www.cnn.com/2024/01/11/tech/al-gore-is-officially-too-old-for-apple/index.html#:~:text=He's%20also%20served%20as%20the,according%20to%20an%20SEC%20filing."> </a>CNN, Gore received $376,894 in 2023 as compensation for serving on Apple&#8217;s board, a position he has held since 2003. That total included $275,022 in stock awards. 2024 was his last year as a board director, as Apple does not allow members to hold a position beyond 75. Since 2001, Gore has also been a senior advisor to Google, where he received significant pre-public stock options.&nbsp;
See Also: Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
Like many former presidents and VPs, Gore&#8217;s time out of public service was when he made most of his money. His assets at the end of the Clinton administration were between $780,000 and $1.9 million, derived chiefly from his family&#8217;s land holdings in Tennessee and stock holdings, according to<a href="https://pfds.opensecrets.org/N00008954_99.pdf"> financial disclosure forms</a> revealed through<a href="https://www.cbsnews.com/news/the-making-of-a-businessman-how-al-gore-got-rich/"> </a>CBS News.
<h2 class="wp-block-heading">Current Media</h2>
Another Gore masterstroke was co-founding Current Media in 2002. When the company went public six years later, his annual compensation was $1.05 million. Gore also became a partner at pivotal Silicon Valley venture capital firm <a href="https://www.benzinga.com/markets/24/08/40113420/mark-cuban-and-other-venture-capitalists-pledge-support-for-kamala-harris-whos-on-the-list">Kleiner Perkins Caufield &amp; Byers</a>. When Current Media was sold to Al Jazeera for $500 million in 2013, Gore personally netted between $70 million and $100 million, according to the Washington Post.&nbsp;
While Gore&#8217;s loss in the controversial 2000 election to Bush was personally wrenching, his accountants would contend that it was the best thing that could have happened to their client.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-y2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

AAPL

GOOG

SCHW

Former Veep Al Gore Is Renting Out His Suburban DC Home for $9,000/month. Not That He Needs the Money. He's Worth $300M

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease will be presente...

Athira Pharma to present results from Phase 2/3 LIFT-AD trial

Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on&nbsp;TipRanks' Penny Stock Scre...

3 Penny Stocks to Watch Now, 11/5/24

"We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating dru...

Athira Pharma reports Q3 EPS (75c), consensus (71c)

Athira Pharma GAAP EPS of -$0.75 misses by $0.04

JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company's shares closed yesterday...

JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)

Athira Pharma, Inc. ( ($ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors...

Athira Pharma Reports Q3 2024 Financial Results

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dep...

Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline

Athena Gold upsizes private placement from C$1M to up to C$1.25M

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of rese...

Athira Pharma to pay $4M to settle False Claims Act allegations

Alterity surges after mid-stage trial data for lead asset

AHNR

ATHA

TOVX

VSTE

Press Releases

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Health Care

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Comments

Athira Pharma

Athira Pharma (ATHA) Opciones

Athira Pharma (NASDAQ:ATHA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL